Tekturna portfolio is history.
Diovan & Reclast have only a few months left.
Focalin XR goes generic in OCT and the bigger doses do not generate enough Rx's
Exelon Patch is less than 300 mill a yr
Exforge will go the way of Lotrel
Fanapt is a bust @ 45 mill & no indications
Primary Care & Neuro/Psych are going to be a shadow of its former self. We don't need a mole or insider to figure out whats next. Senior management have already said it will be soon. VP's and GM's are leaving everyday.
There is now way the USA is going to require more than 1000 reps to promote whats left. Being over 40 with a young family I am concerned but I hope this unfolds quickly so that I can get back to thinking about work or working hard to find work
At the end of the day Novartis is in bad shape
Diovan & Reclast have only a few months left.
Focalin XR goes generic in OCT and the bigger doses do not generate enough Rx's
Exelon Patch is less than 300 mill a yr
Exforge will go the way of Lotrel
Fanapt is a bust @ 45 mill & no indications
Primary Care & Neuro/Psych are going to be a shadow of its former self. We don't need a mole or insider to figure out whats next. Senior management have already said it will be soon. VP's and GM's are leaving everyday.
There is now way the USA is going to require more than 1000 reps to promote whats left. Being over 40 with a young family I am concerned but I hope this unfolds quickly so that I can get back to thinking about work or working hard to find work
At the end of the day Novartis is in bad shape